Drugs / mRNA-2752
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02872025 | Dec 2016 → Mar 2026 overdue | ductal breast carcinoma in situ | Laura Esserman | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03739931 | Nov 2018 → Aug 2025 | hematopoietic and lymphoid cell neoplasm | ModernaTX, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | ModernaTX, Inc. | Results Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update q4web.com ↗
Initial data from the ongoing Phase 1 study of OX40L/IL-23/IL-36γ (Triplet) (mRNA-2752) in patients with accessible solid tumors and lymphoma showed that mRNA-2752 given in combination with AstraZeneca's durvalumab (IMFINZI®) was tolerated at all dose levels tested and elicited evidence of anti-tumor activity |
| 2021-11-12 | ModernaTX, Inc. | Results Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting q4web.com ↗
The data showed that the Company’s mRNA Triplet program given in combination with AstraZeneca’s durvalumab (IMFINZI®) was tolerated at all dose levels tested and elicited evidence of anti-tumor activity. |
| 2019-01-30 | ModernaTX, Inc. | Results Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors q4web.com ↗
When combined with checkpoint inhibitors, mRNA-2752 boosted complete response rates in immunosuppressive and in immunologically barren tumor models that are otherwise unresponsive to checkpoint inhibitors. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-2752 | “mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs), dose ranging from 1 mg to 4 mg, delivered intratumorally, with 2 to 4 doses given 2 to 3 weeks apart.” PMID 39821301 ↗ Mar 2025 |
| Modality | Messenger RNA (mRNA) | “mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs)” PMID 39821301 ↗ Mar 2025 |
| Route | Other | “Injected intralesionally” NCT02872025 ↗ |